Khiron Life Sciences (KHRN.V), one of the first medical marijuana companies to be fully-licensed in Colombia, isn’t concerning itself with the Californian cannabis market.
Instead, the company has set its sights on legalized regions outside the U.S. like Latin America and Europe. These markets may not be as big as California and the U.S., but they are sizable, sustainable and more than available in the nascent multi-billion-dollar global weed marketplace.
Equity.Guru’s Chris Parry spoke with Khiron president, Chris Naprawa, to get a bird’s eye view of the company, the international legal cannabis market, the 2018 farm bill and what the capital markets can expect from Khiron over the next 12 months.
Listen in!Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
Latest posts by Chris Parry (see all)
- Update: Fisticuffs at Hollyburn as high society calls out Bridgemark pair - November 21, 2019
- Defense Metals (DEFN.V) yanking rare earths out of the ground, markets be damned - November 20, 2019
- LiteLink Technologies (LLT.C): Using AI and blockchain tech to build the Uber of cargo - November 18, 2019